Prediction and validation of enzyme and transporter off-targets for metformin
暂无分享,去创建一个
Brian K. Shoichet | Michael J. Keiser | Youcai Zhang | Kathleen M. Giacomini | Sook Wah Yee | Huan-Chieh Chien | Lawrence Lin | Matthew Merski | Aakash Gupta
[1] John Kurhanewicz,et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin , 2014, Proceedings of the National Academy of Sciences.
[2] Tudor I. Oprea,et al. Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..
[3] K. Brouwer,et al. Organic Cation Transporter 1 (OCT1/mOct1) Is Localized in the Apical Membrane of Caco-2 Cell Monolayers and Enterocytes , 2013, Molecular Pharmacology.
[4] D. Murphy,et al. Maintenance of Serotonin in the Intestinal Mucosa and Ganglia of Mice that Lack the High-Affinity Serotonin Transporter: Abnormal Intestinal Motility and the Expression of Cation Transporters , 2001, The Journal of Neuroscience.
[5] R. Arieli,et al. Hypoxic survival differs between two mole rat species (Spalax ehrenbergi) of humid and arid habitats. , 1991, Comparative biochemistry and physiology. A, Comparative physiology.
[6] O. Ogawa,et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. , 2006, Journal of the American Society of Nephrology : JASN.
[7] M. Gershon. Review article: roles played by 5‐hydroxytryptamine in the physiology of the bowel , 1999, Alimentary pharmacology & therapeutics.
[8] K. Giacomini,et al. Interactions of Tyrosine Kinase Inhibitors with Organic Cation Transporters and Multidrug and Toxic Compound Extrusion Proteins , 2011, Molecular Cancer Therapeutics.
[9] B. Hagenbuch,et al. Common Drugs Inhibit Human Organic Cation Transporter 1 (OCT1)-Mediated Neurotransmitter Uptake , 2014, Drug Metabolism and Disposition.
[10] M. Bouchoucha,et al. Metformin and digestive disorders. , 2011, Diabetes & metabolism.
[11] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[12] J. Irwin,et al. Identifying mechanism-of-action targets for drugs and probes , 2012, Proceedings of the National Academy of Sciences.
[13] N. Novak,et al. Histamine and histamine intolerance. , 2007, The American journal of clinical nutrition.
[14] D. Ordóñez,et al. Inhibition of diamine oxidase from porcine kidney by pentamidine and other aminoguanidine compounds. , 1991, Comparative biochemistry and physiology. B, Comparative biochemistry.
[15] G. Coruzzi,et al. An update on histamine H3 receptors and gastrointestinal functions , 1995, Digestive Diseases and Sciences.
[16] Kazuhiro Watanabe,et al. Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. , 2002, Biological & pharmaceutical bulletin.
[17] Dmitri D. Pervouchine,et al. The human transcriptome across tissues and individuals , 2015, Science.
[18] C. Bailey,et al. Accumulation of metformin by tissues of the normal and diabetic mouse. , 1994, Xenobiotica; the fate of foreign compounds in biological systems.
[19] G. Tomkin,et al. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects , 1980, Diabetologia.
[20] Swati S. More,et al. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin , 2010, Pharmacogenetics and genomics.
[21] W. Bardsley,et al. Kinetics of the diamine oxidase reaction. , 1973, The Biochemical journal.
[22] Joanne Wang,et al. Selective Transport of Monoamine Neurotransmitters by Human Plasma Membrane Monoamine Transporter and Organic Cation Transporter 3 , 2010, Journal of Pharmacology and Experimental Therapeutics.
[23] J. Hoffman,et al. Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets , 2013, Nature Reviews Gastroenterology &Hepatology.
[24] R. Ferner,et al. Comparative Tolerability Profiles of Oral Antidiabetic Agents , 1994, Drug safety.
[25] C. Crifó,et al. Inhibition of diamine oxidase by antihistaminic agents and related drugs , 1979, Agents and Actions.
[26] A. D. Miller,et al. Mechanisms of vomiting induced by serotonin-3 receptor agonists in the cat: effect of vagotomy, splanchnicectomy or area postrema lesion. , 1992, The Journal of pharmacology and experimental therapeutics.
[27] R. Neubert,et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). , 2005, Biochemical pharmacology.
[28] H. Bönisch,et al. Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.
[29] B. Viollet,et al. Cellular and molecular mechanisms of metformin: an overview. , 2012, Clinical science.
[30] Shuzhong Zhang,et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. , 2007, The Journal of clinical investigation.
[31] G. Levy. RELATIONSHIP BETWEEN RATE OF ELIMINATION OF TUBOCURARINE AND RATE OF DECLINE OF ITS PHARMACOLOGICAL ACTIVITY. , 1964, British journal of anaesthesia.
[32] G. Baker,et al. Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. , 1995, Progress in brain research.
[33] John P. Overington,et al. An atlas of genetic influences on human blood metabolites , 2014, Nature Genetics.
[34] B. D. De Winter,et al. Histamine H4 receptors in the gastrointestinal tract , 2015, British journal of pharmacology.
[35] K. Giacomini,et al. Targeted Disruption of Organic Cation Transporter 3 Attenuates the Pharmacologic Response to Metformin , 2015, Molecular Pharmacology.
[36] M. Gershon. Review article: serotonin receptors and transporters — roles in normal and abnormal gastrointestinal motility , 2004, Alimentary pharmacology & therapeutics.
[37] C. Day,et al. Effect of metformin on glucose metabolism in the splanchnic bed , 1992, British journal of pharmacology.
[38] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[39] Yuichi Sugiyama,et al. Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin , 2002, Journal of Pharmacology and Experimental Therapeutics.
[40] G. Houen,et al. New tools for studying old questions: antibodies for human diamine oxidase , 2013, Journal of Neural Transmission.
[41] P. Dandona,et al. Diarrhea and Metformin in a Diabetic Clinic , 1983, Diabetes Care.
[42] D. Thakker,et al. Four Cation-Selective Transporters Contribute to Apical Uptake and Accumulation of Metformin in Caco-2 Cell Monolayers , 2015, The Journal of Pharmacology and Experimental Therapeutics.
[43] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[44] G. Coruzzi,et al. Receptors in the gastrointestinal tract. , 1987, Pharmacological research communications.
[45] Brian K. Shoichet,et al. Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4) , 2013, Biochemical pharmacology.
[46] J Mitchell Guss,et al. Structure and inhibition of human diamine oxidase. , 2009, Biochemistry.
[47] G Levy,et al. Propoxyphene and norpropoxyphene plasma concentrations in the anephric patient , 1980, Clinical pharmacology and therapy.
[48] C. Palmer,et al. Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study , 2014, Diabetes.
[49] K. Giacomini,et al. Propoxyphene and norpropoxyphene plasma concentrations after oral propoxyphene in cirrhotic patients with and without surgically constructed portacaval shunt , 1980, Clinical pharmacology and therapeutics.
[50] G Levy,et al. Kinetics of drug action in disease states. II. Effect of experimental renal dysfunction on phenobarbital concentrations in rats at onset of loss of righting reflect. , 1984, The Journal of pharmacology and experimental therapeutics.
[51] B. Viollet,et al. Revisiting the mechanisms of metformin action in the liver. , 2013, Annales d'endocrinologie.
[52] H. B. Woodruff,et al. Cefoxitin and cephamycins: microbiological studies. , 1979, Reviews of infectious diseases.
[53] R. Leurs,et al. Effects of histamine H1‐, H2‐ and H3‐receptor selective drugs on the mechanical activity of guinea‐pig small and large intestine , 1991, British journal of pharmacology.
[54] H. Koepsell,et al. Polyspecific Organic Cation Transporters: Structure, Function, Physiological Roles, and Biopharmaceutical Implications , 2007, Pharmaceutical Research.
[55] T. Illig,et al. Association of single nucleotide polymorphisms in the diamine oxidase gene with diamine oxidase serum activities , 2011, Allergy.
[56] G. Bray,et al. Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.
[57] M. Götz,et al. Histamine‐free diet: treatment of choice for histamine‐induced food intolerance and supporting treatment for chronical headaches , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[58] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[59] H. Koepsell,et al. Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene , 2001, Molecular and Cellular Biology.
[60] A. Schinkel,et al. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.
[61] M. Jutel,et al. Histamine and gut mucosal immune regulation , 2014, Allergy.
[62] J. Tack,et al. REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders , 2007 .
[63] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[64] Gary D Stormo,et al. An Introduction to Sequence Similarity (“Homology”) Searching , 2009, Current protocols in bioinformatics.
[65] W. Lorenz,et al. Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. , 1983, Biochimica et biophysica acta.
[66] P. Rangachari,et al. Probing the "active site" of diamine oxidase: structure-activity relations for histamine potentiation by O-alkylhydroxylamines on colonic epithelium. , 1999, The Journal of pharmacology and experimental therapeutics.
[67] E. Bodner,et al. Purification and characterization of diamine oxidase from porcine kidney and intestine. , 1997, Biochimica et Biophysica Acta.
[68] D. Keppler,et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver , 2009, Hepatology.
[69] J. Morrison,et al. Buffers of constant ionic strength for studying pH-dependent processes. , 1982, Methods in enzymology.
[70] D. Thakker,et al. Mechanisms Underlying Saturable Intestinal Absorption of Metformin , 2008, Drug Metabolism and Disposition.
[71] Andrej Sali,et al. Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling. , 2013, Journal of medicinal chemistry.
[72] G. Banchelli,et al. Guanabenz as inhibitor of copper-containing amine oxidases , 1986, Agents and Actions.
[73] Osamu Ogawa,et al. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. , 2007, Biochemical pharmacology.
[74] S. Masuda,et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. , 2005, Drug metabolism and pharmacokinetics.
[75] H. Endou,et al. Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. , 2010, Journal of pharmacological sciences.
[76] C. Beasley,et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. , 2000, Clinical therapeutics.
[77] M. Danhof,et al. Kinetics of drug action in disease states. VII. Effect of experimental renal dysfunction on the pharmacodynamics of ethanol in rats. , 1985, The Journal of pharmacology and experimental therapeutics.
[78] E. Lundberg,et al. Towards a knowledge-based Human Protein Atlas , 2010, Nature Biotechnology.
[79] S. Durham,et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. , 2015, The Journal of allergy and clinical immunology.
[80] C. Bailey,et al. Effects of metformin on bile salt transport by monolayers of human intestinal Caco‐2 cells , 2002, Diabetes, obesity & metabolism.